European Union - English - EMA (European Medicines Agency)

mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - antithrombotic agents - clopidogrel/acetylsalicylic acid mylan is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (asa).clopidogrel/acetylsalicylic acid mylan is a fixed-dose combination medicinal product for continuation of therapy in:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionst segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - aspirin 100mg; clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg clopidogrel;  ;   - film coated tablet - 75mg/100mg - active: aspirin 100mg clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg clopidogrel     excipient: carnauba wax colloidal silicon dioxide hydrogenated castor oil hyprolose macrogol 6000 maize starch mannitol microcrystalline cellulose opadry pink 32k24375 stearic acid - co-plavix is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: · unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death and refractory ischaemia). coplavix is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). · st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, co-plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.